Milestone Pharmaceuticals Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Milestone Pharmaceuticals Inc. (MIST) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $2.57 per share for the 9-month period ending 2020-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2021-11-12
- Milestone Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2020-03-31 was $2.12.
- Milestone Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2018-03-31 was $1.10.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month |
|---|---|---|---|
| 2020-09-30 | $2.57 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $2.57 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | $2.12 10-Q · filed 2021-05-17 | ||
| 2018-09-30 | $1.10 10-Q · filed 2019-11-13 | ||
| 2018-06-30 | $1.10 10-Q · filed 2019-08-13 | ||
| 2018-03-31 | $1.10 10-Q · filed 2019-06-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |